Published on
December 25, 2025
- 08:51 GMT
AlloDx Unveils SuperNAT Platform: Breakthrough in Nephrin Antibody Detection for Podocyte Disease
The SuperNAT demonstrates 48.6% higher sensitivity than conventional ELISA, with its clinical validation data accepted for poster at ASN Kidney Week 2025. WASHINGTON, DC, UNITED STATES, December 25, 2025 /EINPresswire.com/ -- AlloDx, a pioneer in …
Distribution channels:
Business & Economy, Companies
...
